 Azetidines
"Azetidines" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
No definition found.
| Descriptor ID |
D001384
|
| MeSH Number(s) |
D03.383.082.301
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Azetidines".
Below are MeSH descriptors whose meaning is more specific than "Azetidines".
This graph shows the total number of publications written about "Azetidines" by people in this website by year, and whether "Azetidines" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 1 | 1 | | 2001 | 1 | 0 | 1 | | 2002 | 1 | 0 | 1 | | 2003 | 2 | 1 | 3 | | 2005 | 2 | 1 | 3 | | 2006 | 1 | 0 | 1 | | 2007 | 1 | 0 | 1 | | 2008 | 0 | 1 | 1 | | 2011 | 1 | 0 | 1 | | 2014 | 1 | 2 | 3 | | 2017 | 2 | 0 | 2 | | 2018 | 1 | 1 | 2 | | 2020 | 1 | 0 | 1 | | 2021 | 1 | 0 | 1 | | 2022 | 1 | 1 | 2 | | 2024 | 2 | 1 | 3 |
To return to the timeline, click here.
Below are the most recent publications written about "Azetidines" by people in Profiles.
-
Hamilton E, Oliveira M, Turner N, Garc?a-Corbacho J, Hernando C, Ciruelos EM, Kabos P, Ruiz-Borrego M, Armstrong A, Patel MR, Vaklavas C, Twelves C, Boni V, Incorvati J, Brier T, Gibbons L, Klinowska T, Lindemann JPO, Morrow CJ, Sykes A, Baird RD. A phase I dose escalation and expansion trial of the next-generation oral SERD camizestrant in women with ER-positive, HER2-negative advanced breast cancer: SERENA-1 monotherapy results. Ann Oncol. 2024 Aug; 35(8):707-717.
-
Wang LL, Tuohy S, Xu KL, Nace A, Yang R, Zheng Y, Burdick JA, Cotsarelis G. Local and Sustained Baricitinib Delivery to the Skin through Injectable Hydrogels Containing Reversible Thioimidate Adducts. Adv Healthc Mater. 2024 05; 13(12):e2303256.
-
Konopleva MY, Dail M, Daver NG, Garcia JS, Jonas BA, Yee KWL, Kelly KR, Vey N, Assouline S, Roboz GJ, Paolini S, Pollyea DA, Tafuri A, Brandwein JM, Pigneux A, Powell BL, Fenaux P, Olin RL, Visani G, Martinelli G, Onishi M, Wang J, Huang W, Dunshee DR, Hamidi H, Ott MG, Hong WJ, Andreeff M. Venetoclax and Cobimetinib in Relapsed/Refractory AML: A Phase 1b Trial. Clin Lymphoma Myeloma Leuk. 2024 Jun; 24(6):364-374.
-
McQueen RB, Baum SJ, Louie MJ, Sasiela WJ, Bilitou A, Shah H, Nash B, Gillard KK, Ray KK. Potential Cardiovascular Events Avoided with Bempedoic Acid Plus Ezetimibe Fixed-Dose Combination Compared with Ezetimibe Alone in Patients with Atherosclerotic Cardiovascular Disease Taking Maximally Tolerated Statins. Am J Cardiovasc Drugs. 2023 Jan; 23(1):67-76.
-
Zehra Okus F, Busra Azizoglu Z, Canatan H, Eken A. S1P analogues SEW2871, BAF312 and FTY720 affect human Th17 and Treg generation ex vivo. Int Immunopharmacol. 2022 Jun; 107:108665.
-
Robert C, Lewis KD, Gutzmer R, Stroyakovskiy D, Gogas H, Protsenko S, Pereira RP, Eigentler T, Rutkowski P, Demidov L, Caro I, Forbes H, Shah K, Yan Y, Li H, McArthur GA, Ascierto PA. Biomarkers of treatment benefit with atezolizumab plus vemurafenib plus cobimetinib in BRAFV600 mutation-positive melanoma. Ann Oncol. 2022 05; 33(5):544-555.
-
Shimizu M, Inoue N, Mizuta M, Irabu H, Okajima M, Honda Y, Nihira H, Izawa K, Yachie A, Wada T. Successful treatment of spondyloenchondrodysplasia with baricitinib. Rheumatology (Oxford). 2021 02 01; 60(2):e44-e46.
-
Tuttle KD, Waugh KA, Araya P, Minter R, Orlicky DJ, Ludwig M, Andrysik Z, Burchill MA, Tamburini BAJ, Sempeck C, Smith K, Granrath R, Tracy D, Baxter J, Espinosa JM, Sullivan KD. JAK1 Inhibition Blocks Lethal Immune Hypersensitivity in a Mouse Model of Down Syndrome. Cell Rep. 2020 11 17; 33(7):108407.
-
Ascierto PA, Ribas A, Larkin J, McArthur GA, Lewis KD, Hauschild A, Flaherty KT, McKenna E, Zhu Q, Mun Y, Dr?no B. Impact of initial treatment and prognostic factors on postprogression survival in BRAF-mutated metastatic melanoma treated with dacarbazine or vemurafenib???cobimetinib: a pooled analysis of four clinical trials. J Transl Med. 2020 Aug 03; 18(1):294.
-
Ribas A, Daud A, Pavlick AC, Gonzalez R, Lewis KD, Hamid O, Gajewski TF, Puzanov I, Wongchenko M, Rooney I, Hsu JJ, Yan Y, Park E, McArthur GA. Extended 5-Year Follow-up Results of a Phase Ib Study (BRIM7) of Vemurafenib and Cobimetinib in BRAF-Mutant Melanoma. Clin Cancer Res. 2020 01 01; 26(1):46-53.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|